	Softgel capsules have long been recognized by the pharmaceutical community and patients as effective dosage forms for oral drug delivery. Softgels traditionally use gelatin as the film-forming polymer in the capsule shell, but OptiShell softgel technology uses plant-derived polysaccharides. The different physico-chemical and thermo-mechanical properties of OptiShell capsules allow for encapsulation of a wider range of fill formulation types, including semi-solids formulated at higher temperatures.

	Catalent’s OptiShell technology was one of three finalists selected by a panel of pharma industry experts, and the award was presented at a ceremony on October 13th, at CPhI Worldwide.

	“OptiShell technology may provide an opportunity for formulators to develop semi-solid, extended release formulations with improved and more consistent therapeutic effectiveness. The ‘hot-filling’ process enables delivery of semi-solid formulations in a patient preferred dose form, while the semi-solid matrix offers extended release profiles that can reduce the maximum API concentration in the bloodstream, decrease the dosing frequency, and, therefore, potentially increase patient adherence,” commented Dr. Aris Gennadios, Catalent’s president of Softgel Technologies, in the press release.

Dosage Forms

PharmTech News

Solid/Semi-Solid Dosage

Supplier News

Catalent Pharma Solutions won the “Innovation in Process and Formulation Development” category at the annual CPhI Pharma Awards, for its OptiShell softgel technology platform.